Article Details

ASCO: Alpine reports 61% 'clinical benefit' in early trial of CD28-targeted immuno-oncology drug

Retrieved on: 2021-06-07 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

ASCO: Alpine reports 61% 'clinical benefit' in early trial of CD28-targeted immuno-oncology drug. View article details on HISWAI: https://www.fiercebiotech.com/research/asco-alpine-reports-61-clinical-benefit-early-trial-cd28-targeted-immuno-oncology-drug

Excerpt

But the company is also pursuing one strategy for stimulating CD28 to improve the immune response to cancer—and it has early evidence its plan ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up